Introduction
A recent survey showed that 8% of an American population has elevated serum aminotransferase levels [1] . Most of these persons have non-alcoholic fatty liver (NAFL), a condition characterized by steatosis without inflammation or fibrosis. It is a benign and reversible condition. However, in 20% of cases liver histology shows necroinflammation and some degree of pericellular fibrosis. This is called non-alcoholic steatohepatitis (NASH). NAFL can be considered as a precursor lesion of NASH, which can progress to cirrhosis [2] . To complete the terminology, both NAFL and NASH are non-alcoholic fatty liver diseases (NAFLDs). more common than hitherto realized [5] . For further details on the epidemiology of NASH see Bellentani et al. in this issue.
The transition of NAFL to NASH is not clearly demarcated. Inflammation and fibrosis mark the difference; both are features of NASH, not of NAFL. Thus, for the differentiation of NAFL and NASH one needs a liver biopsy [6] . NASH is a major cause of cryptogenic liver cirrhosis. The diagnosis of NASH is missed in these patients because the steatosis often disappears once cirrhosis develops [2, 7] . The prognosis of NASHrelated cirrhosis was worse than that of hepatitis Crelated cirrhosis in one study (3 year survival 50% versus 70% [8]), but showed no difference in another study [9] . Both conditions may give rise to hepatocellular carcinoma [2, [8] [9] [10] .
Pathology
The pathology of NASH has been described by Ludwig et al. [11] . NASH is characterized by macrovesicular steatosis, hepatocellular ballooning and lobular inflammation. Perisinusoidal or pericellular (chickenwire) fibrosis is present in acinar zone 3. Mallory bodies are occasionally seen but are not necessary for the diagnosis. Liver histopathology in alcoholic liver disease and NASH is very similar. However, cholestasis is not a feature of NASH but often occurs in alcoholic liver disease. Likewise central-central and central-portal bridging necrosis frequently occurs in alcoholic liver disease but is uncommon in NASH [12] . Macrovesicular steatosis occurs in a variety of liver diseases including hepatitis C, Wilson's disease, alcoholic liver disease, primary biliary cirrhosis and toxic liver injury. All the features of NASH may be present in hepatitis C, but in hepatitis C inflammation and fibrosis are mainly localized in the portal or periportal areas [13] . Ballooning degeneration, Mallory's hyaline and fibrosis are discriminant features suggestive of progressive NASH [14] . See the review by Hü bscher in this issue.
Associations
NASH is associated with central obesity, diabetes type 2, syndrome X (obesity, dyslipidaemia, insulin resistance and hypertension), polycystic ovary syndrome and hypertriglyceridaemia [15] . Almost all patients with NASH are insulin resistant. It is clear that insulin resistance must play a key role in the pathogenesis of NASH [16, 17] . However, insulin resistance, hyperinsulinaemia and hyperglycaemia are not limited to NASH but also occur in other liver diseases such as hepatitis C [18, 19] . As for obesity, one does not have to be morbidly obese to have NASH. In moderately overweight patients with elevated serum liver enzymes (BMI . 25 kg/m 2 ), NASH with septal fibrosis was present in 30% and cirrhosis in 11% [20] . NASH is related to diabetes mellitus type 2 but its true incidence among these patients is unknown [21] . NASH is increasingly recognized among obese children [22] .
Diagnosis
NASH is an under-diagnosed disease. For its diagnosis a liver biopsy is required. This undoubtedly constitutes a threshold for its detection among obese and diabetic populations. Indeed a liver biopsy in obese people carries an increased risk. Moreover, a liver biopsy is too invasive for screening purposes. Ultrasonography misses about one third of cases [23, 24] . Most patients with NASH have elevated serum aminotransferases and many have some degree of hepatomegaly. However, normal liver enzymes and a normal liver size do not exclude the diagnosis. In target groups, such as obese persons, patients with diabetes mellitus type 2 and patients on total parenteral nutrition, elevated liver enzymes suggest NASH and a liver biopsy should lead to the diagnosis. It is clear that new diagnostic markers or non-invasive procedures to detect and quantify liver fat are needed. Magnetic resonance proton spectroscopy of the liver may be such a procedure [25, 26] .
Pathogenesis
In the pathogenesis of NASH two steps or 'hits' can be recognized ( Fig. 1 ). Prolonged over-nutrition causes steatosis. Insulin, free fatty acids (FFAs) and glucose stimulate SREBP-1c, a key regulator of hepatic triglyceride synthesis [27] . Its main action is the stimulation of lipogenic enzymes such as acetyl-CoA carboxylase, fatty acid synthase, acetyl-CoA synthetase, glycerol-3phosphate acyltransferase, and stearoyl-CoA desaturase-1 (SCD-1). SCD-1 catalyses the synthesis of monounsaturated fatty acids that are necessary components in the synthesis of triglycerides [28] . SREBP-1 also stimulates enzymes that are important for the generation of NADPH, an essential co-factor in lipogenesis. Moreover, SREBP-1 stimulation is directly involved in insulin resistance [29, 30] .
Fat accumulation in the liver is the sine qua non, the 'first hit'. Fat per se is not toxic and fat accumulation, to a certain degree, is a physiological response. In many species fat in the liver constitutes a rapidly mobilizable source of energy. For instance, migratory birds increase their liver (and body) weight considerably before migration. During the long flights of migration, triglycerides are hydrolysed and FFAs are used as the energy source for muscle action. However, fat in the liver is not innocuous. Fat makes the liver vulnerable to endotoxins and impairs liver regeneration [31] [32] [33] [34] . Impairment of liver regeneration may be mediated by p53, a protein with tumour suppressor activity that appears to be upregulated in steatosis [35] .
Reactive oxygen species (ROS) and inflammation represent the 'second hit'. FFAs, in fact, can deliver both hits. They are the building blocks of triglyceride synthesis and, when in abundance, contribute to hepatic steatosis. FFAs also are activators of the peroxisomal proliferator-activated receptor AE, PPAR-AE. This is a master regulator of FFA metabolism. It stimulates mitochondrial and peroxisomal â-oxidation [36] . PPAR-AE target genes include carnitine palmitoyltransferase-1, an enzyme that is necessary for the uptake of long chain fatty acids into mitochondria, acyl-CoA oxidase and very long chain acyl-CoA dehydrogenase. PPAR-AE also induces the expression of several cytochromes P450, in particular Cyp2E1 and Cyp4A [37] [38] [39] [40] . These enzymes are elevated in patients with NASH [41, 42] . The role of PPAR-AE in the pathogenesis of NASH is complex. PPAR-AE knockout mice on a high-fat diet develop severe hepatic steatosis. Activation of PPAR-AE in mice on a high-fat diet prevents triglyceride accumulation [43] . Oxidation of FFAs removes the principal substrate for lipogenesis. The price to pay, however, is some degree of oxidant stress. During FFA oxidation, ROS are produced that, when in excess, may give rise to oxidant stress. Continuous and excessive ROS production causes oxidant stress and this may set the scene for the development of NASH. However, inflammation is a major contributing factor in the transition of NAFL to NASH. Here, also, FFAs may play a key role. They directly stimulate IkB/NFkB, factors involved in the inflammation cascade [44, 45] . Moreover, adipose tissue expresses TNF-AE, interleukin 6 and inducible nitric oxide synthase (iNOS) [46] . Therefore obesity is a pro-Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. From fat to injury, from injury to cirrhosis. Free fatty acids are taken up in the hepatocytes where they are either metabolized via peroxisomal or mitochondrial â-oxidation or stored as triglycerides. The insulin-resistant state favours lipolysis in the adipose tissues and, through activation of SREBP, insulin stimulates hepatic free fatty acid (FFA) synthesis and lipogenesis. The net result is hepatic fat accumulation. FFAs activate PPAR-AE and thereby their own degradation by â-oxidation. This contributes to a healthy balance of supply and degradation. However, continuous and superfluous FFA oxidation may cause the generation of excessive amounts of reactive oxygen species (ROS). Enzymes of the cytochrome P-450 family, in particular CYP 2E1 and CYP 4A, are also induced by PPAR-AE and contribute to ROS formation. ROS causes oxidant stress with the peroxidation of abundantly available lipids in the liver and activation of NFkB, a major factor in the inflammation cascade. In addition, cytokines are produced in adipocytes as well as in Kupffer cells. TGF-â stimulates hepatic stellate cells to produce collagen and cause liver fibrosis. In addition, these cells transform into myofibroblasts with more collagen formation and an increase of intrahepatic vascular resistance and portal hypertension. Chemokines attract monocytes and neutrophils with inflammation, more oxidant stress, hepatocellular necrosis, apoptosis and injury as a result. Meanwhile hepatic regeneration is impaired through activation of p53.
inflammatory condition and likewise in obese persons the liver is exposed to cytokines produced in their adipose tissues. Moreover, TNF-AE and interleukin 1 and 6 reduce the activity of Jun N-terminal kinase and this inactivates insulin receptor substrate (IRS-1) in muscle with insulin resistance as a consequence [47] . This likely also occurs in liver (IRS-2). Thus, insulin resistance is both a cause and consequence of NASH.
Whether intestinal dysmotility and bacterial overgrowth also contribute to NASH is controversial. Bacterial overgrowth of the small intestine has been reported in NASH, and conditions with bacterial overgrowth such as jejuno-ileal bypass cause NASH [48] . One can hypothesize that lipophilic endotoxins from the gut may accumulate in the fat of hepatocytes from where they are slowly but continuously released. This stimulates Kupffer cells to produce TNF-AE, interleukin 1 and 6 and the pro-fibrotic cytokine transforming growth factor-â (TGF-â), which stimulates the transformation of hepatic stellate cells into collagen-producing myofibroblasts. In addition, chemokines are produced that attract monocytes and neutrophils which greatly contribute to the perpetuation of oxidative stress and cell injury [49] [50] [51] .
Adiponectin deficiency contributes to the development of NASH. Adiponectin (also known as 30 kDa adipocyte complement-related protein, Acrp30) is a hormone produced by peripheral adipose tissue. It circulates in the blood in a globular form and as a full-length molecule. Liver and muscle have adiponectin receptors. Stimulation of the adipoR2 receptor in the liver leads to activation of AMP-activated protein kinase and PPAR-AE [52, 53] . Thus, adiponectin increases fatty acid â-oxidation, thereby decreasing the hepatic triglyceride content and ameliorating insulin resistance. Adiponectin-deficient mice show an increased sensitivity to liver damage induced by carbon tetrachloride. The liver damage in these mice could be significantly attenuated by adminstration of recombinant adiponectin [54] . Also, other studies show that adiponectin has a protective effect on the liver wherein it decreases necrosis and inflammation [55] . In NASH, obesity and type 2 diabetes mellitus, adiponectin production is decreased [56] . In the absence of this protective factor the liver is vulnerable to the action of cytokines and ROS. For details about the pathophysiology see the article by Pessayre et al. in this issue.
Therapy (Table 1) Treatment of NASH has to be seen against this pathophysiological background. Lifestyle adjustments should be tried first: weight reduction in combination with exercise is the most rational remedy [49] . Unfortunately, compliance in obese people is low and episodic rapid weight loss, followed by binge eating and weight gain, is counter-productive. Thus, diets often may make things worse, in particular when they lead to a yoyo effect on body weight. Programmed exercise would be a rational therapy. It diverts the fatty acids away from the liver to be metabolized in the muscles and it decreases insulin resistance.
Diets with polyunsaturated fatty acids are effective and have a sound physiological background. Polyunsaturated fatty acids stimulate PPAR-AE and repress the sterol regulatory element-binding protein SREBP-1
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Effective in small randomized study [87] [57]. Indeed, disruption of the SREBP-1 gene in leptindeficient ob/ob mice causes a reduction of lipogenesis and clearance of liver fat but did not reduce obesity and overall insulin resistance [58] . In ob/ob mice, diets enriched with polyunsaturated fatty acids reduced both hepatic steatosis and insulin resistance [59] .
Stimulation of PPAR-AE by drugs could be an effective therapy. Gemfibrozil showed a positive effect in a small pilot study [60] . A recent study showed that arachidylamido-cholanoic acid, a liver-specific agent with presumed PPAR-AE agonistic activity, prevents diet-induced fatty livers in rodents [61] . Drug therapy should aim at several levels and it is unlikely that a single drug could do the job. Anti-inflammatory, anti-oxidative, cytoprotective and lipolytic agents have been tried but given alone none of these has been shown to be very effective. For example, supplementation with vitamin E is ineffective [49] but vitamin E in combination with vitamin C has been shown to reduce fibrosis in a small randomized study [62] .
Current trials focus on drugs that increase insulin sensitivity. Metformin was successfully tried in an animal model of NASH, the leptin-deficient ob/ob mouse [63] . In an uncontrolled clinical trial metformin reduced insulin resistance, decreased aminotransferase levels and reduced hepatomegaly [64] but larger randomized controlled studies are needed to prove its effect. The PPAR-ª ligand troglitazone also showed benefit in NASH patients but later was implicated in severe liver toxicity [65, 66] . Rosiglitazone has been tried with success in a small uncontrolled trial. Twenty-five of 30 patients with NASH completed 48 weeks of treatment. Serum aminotransferase levels and necro-inflammatory score, steatosis and fibrosis improved in these patients but undesirable weight gain occurred in 67% of these patients [67] . A recent trial showed that pioglitazone may be effective [68] . The thiazolidinediones have a direct effect on PPAR-ª in hepatic stellate cells. Activation of PPAR-ª in hepatic stellate cells retards collagen synthesis and fibrosis both in vitro and in vivo [69] . Thus, PPAR-AE and PPAR-ª agonists, as well as drugs that stimulate adiponectin release from adipose tissue, may hold promise for treatment of NASH. Activation of PPAR-ä to stimulate â-oxidation in muscle may be another way to go [70] .
Bile acid binding resins have been used as serum cholesterol lowering agents. An increase in serum triglycerides has been noted as a side effect of this therapy [71] . In contrast, treatment of gallstone patients with chenodeoxycholic acid, but not ursodeoxycholic acid, is accompanied by a decrease of serum triglycerides [72, 73] . Auwerx and colleagues have elucidated the relationship between bile acid and triglyceride metabolism [74] . KK-A y mice represent an animal model with diabetes mellitus type 2, massive obesity and hepatic steatosis. Addition of cholic acid to the diets of these mice significantly decreased the steatosis. Bile acids are ligands for the farnesoid X receptor FXR. SREBP expression is controlled by the liver X receptor, LXR. Activation of SREBP by LXR is inhibited by SHP, the small heterodimer partner protein. SHP is a target gene of FXR and this explains why activation of FXR decreases triglyceride synthesis in the liver. Nontoxic ligands of FXR may thus represent potential future antilipidaemic drugs. It is of note that ursodeoxycholic acid is not an FXR ligand and therefore cannot be expected to be of benefit. The management of NASH is described in this issue by Reid and Sanyal.
Conclusion
NASH is an underdiagnosed disease. The incidence among patients with diabetes mellitus type 2 and obese people is particularly high. NASH may lead to progressive liver disease, cirrhosis and hepatocellular carcinoma. It also occurs in obese children. For its unequivocal diagnosis a liver biopsy is necessary. Insulin resistance, steatosis, oxidative stress and inflammation play a major role in its pathogenesis and disease progression. Gradual weight reduction and exercise programmes constitute the most rational therapies but are hard to sustain. Medical therapy aims at amelioration of the insulinresistant state and various drugs for this are under trial. The role of adiponectin and its possible therapeutic implications need to be investigated. 
